Rexulti ^*

This text is for informational purposes only. Please consult a doctor or pharmacist before using any medication. 

Read the information leaflet that comes with the medication.

Most people who use Rexalti do not experience any adverse side effects. Doctors prescribe this medication because they assess the benefits of such treatment outweigh any likely unwanted effects.

There are possible serious side effects that may occur while using this medication:

• In elderly patients with dementia-related psychosis, there is an increased risk of death   
• Increased levels of suicidal actions and thoughts
• Issues with body temperature regulation, feeling too warm.
• Involuntary, repetitive body movements (tardive dyskinesia) that may become permanent.
• Metabolic changes such as increases in blood sugar, cholesterol, and triglyceride levels.

Some of the common side effects that have been reported include:

• Headaches
• Tiredness
• Restlessness and an urge to move (akathisia)
• Dizziness
• Increase in appetite and weight
• Anxiety
• Constipation
• Diarrhea
• Nausea

Not all side effects are listed here. If these or other unlisted symptoms persist or worsen, consult a healthcare provider or pharmacist.

Major Depressive Disorder (MDD)

Brexpiprazole is approved as an adjunctive treatment for adults with MDD who have had an inadequate response to antidepressant therapy. Clinical studies have demonstrated that adding brexpiprazole to existing antidepressant regimens can lead to significant improvements in depressive symptoms, including mood, sleep disturbances, and irritability.

Schizophrenia

For adults and adolescents aged 13 years and older with schizophrenia, brexpiprazole has been shown to reduce both positive symptoms (e.g., hallucinations, delusions) and negative symptoms (e.g., social withdrawal, lack of motivation). Its favorable side effect profile, particularly regarding extrapyramidal symptoms, makes it a viable option for long-term management.

Agitation in Alzheimer’s Disease

In May 2023, the FDA approved brexpiprazole for the treatment of agitation associated with dementia due to Alzheimer’s disease. This approval was based on clinical trials demonstrating its efficacy in reducing agitation symptoms such as restlessness, verbal outbursts, and physical aggression. Brexpiprazole is the first medication approved for this specific indication.